Symbol="ALGS"
AssetType="Common Stock"
Name="Aligos TherapeuticsÂ Inc"
Description="Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California."
CIK="1799448"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="43798900"
EBITDA="-83857000"
PERatio="None"
PEGRatio="None"
BookValue="1.974"
DividendPerShare="0"
DividendYield="0"
EPS="-1.94"
RevenuePerShareTTM="0.329"
ProfitMargin="0"
OperatingMarginTTM="-6.11"
ReturnOnAssetsTTM="-0.323"
ReturnOnEquityTTM="-0.702"
RevenueTTM="14059000"
GrossProfitTTM="-71170000"
DilutedEPSTTM="-1.94"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.059"
AnalystTargetPrice="4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.788"
PriceToBookRatio="0.351"
EVToRevenue="69.48"
EVToEBITDA="0.793"
Beta="2.382"
num_52WeekHigh="2.41"
num_52WeekLow="0.84"
num_50DayMovingAverage="1.107"
num_200DayMovingAverage="1.196"
SharesOutstanding="39847800"
DividendDate="None"
ExDividendDate="None"
symbol="ALGS"
open="0.98"
high="1.03"
low="0.97"
price="0.98"
volume="69067.00"
latest_trading_day="2023-07-05"
previous_close="1.00"
change="-0.02"
change_percent="-2.0000%"
aroon_positive_momentum_days="51"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="51"
Volume_recent_avg="179176"
Change_recent_avg="-0.01"
Delta_recent_avg="0.12"
Variance_recent_avg="0.06"
Change_ratio_recent_avg="-0.99"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="51"
Aroon_momentum_negative="49"
image_negative_thumbnail_id_1="1112"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0145.jpeg"
image_negative_thumbnail_id_2="161"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0015.jpeg"
image_neutral_thumbnail_id_1="538"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0061.jpeg"
image_neutral_thumbnail_id_2="573"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0026.jpeg"
image_positive_thumbnail_id_1="952"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0114.jpeg"
image_positive_thumbnail_id_2="957"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0119.jpeg"
image_professor_thumbnail_id_1="1186"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
